Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

289
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
289
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

271
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
271
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

398
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
398
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

434
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
434
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

285
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
285
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

268
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
268

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of recombinant human thrombopoietin (rhTPO) in critically ill patients with severe thrombocytopenia: A single-center retrospective cohort study.

International immunopharmacology·2026
Same author

Complement C5a/C5aR1 pathway facilitates glioblastoma progression via fostering glioma stem cell-macrophage symbiosis.

Journal of neuroinflammation·2026
Same author

Factors influencing delays in seeking medical care among elderly patients with pulmonary tuberculosis in Ningbo: a study conducted from 2015 to 2023.

Journal of health, population, and nutrition·2026
Same author

Non-equilibrium criticality-enhanced quantum sensing with superconducting qubits.

Science bulletin·2026
Same author

Intestinal Epithelial Cell Ferroptosis in Ulcerative Colitis: Pathogenesis, Signaling Networks, and Therapeutic Implications.

Current medical science·2026
Same author

Mechanical regulation of microenvironment remodeling in brain tumors: from mechanism to therapy.

Journal of neuroinflammation·2026

Related Experiment Video

Updated: Nov 8, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

606

Compound Sophorae Decoction: treating ulcerative colitis by affecting multiple metabolic pathways.

Zong-Chao Hong1, Quan Cai2, He-Zhen Wu3

  • 1Hubei University of Chinese Medicine, Wuhan 430065, China; Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan 430061, China.

Chinese Journal of Natural Medicines
|April 20, 2021
PubMed
Summary

This study used metabonomics to identify new ulcerative colitis (UC) biomarkers and found Compound Sophorae Decoction (CSD) effectively modulated these, suggesting CSD impacts multiple metabolic pathways in UC treatment.

Keywords:
BiomarkerCompound Sophorae DecoctionLC-MS/MSMetabolomicsUlcerative colitis

More Related Videos

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.0K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.5K

Related Experiment Videos

Last Updated: Nov 8, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

606
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.0K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.5K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Gastroenterology

Background:

  • Ulcerative colitis (UC) is a chronic, difficult-to-treat intestinal inflammatory disease.
  • Identifying novel metabolite biomarkers is crucial for understanding UC, enabling early diagnosis, and elucidating drug mechanisms.
  • Compound Sophorae Decoction (CSD) is a traditional empirical formula for UC, but its therapeutic mechanism remains unclear.

Purpose of the Study:

  • To investigate endogenous metabolic changes in UC rats.
  • To evaluate the effects of CSD on metabolic pathways in UC using a metabonomics approach.

Main Methods:

  • Utilized Liquid Chromatography-Mass Spectrometry/Mass Spectrometry (LC-MS/MS) for metabolomics analysis.
  • Induced UC in rats using TNBS enema as the experimental model.
  • Performed statistical and pathway enrichment analyses for metabolic profiling and biomarker identification.

Main Results:

  • Identified 36 potential biomarkers with significant differences between UC and normal rat groups.
  • Demonstrated that CSD treatment modulated the levels of these identified biomarkers.
  • Observed that CSD's efficacy in UC involves the regulation of multiple metabolic pathways.

Conclusions:

  • Metabonomics approach successfully identified significant metabolic alterations in UC rats.
  • CSD demonstrates therapeutic efficacy in UC by modulating key metabolic pathways and biomarkers.
  • This study provides a foundation for understanding CSD's mechanism of action in treating ulcerative colitis.